Feedback
Settings

Settings

Goto Application

126,004 results
Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07H

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 12,601
1.20250206770CAP COMPOUNDS AND RNAS COMPRISING THE SAME
US - 26.06.2025
Int.Class C07H 21/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
02with ribosyl as saccharide radical
 Appl.No 18990530 Applicant Helix Nanotechnologies Inc Inventor Nikhil Dhar

Disclosed herein are 5′ cap structures comprising a 2′-O-acetyl ribose. Also provided herein are polyribonucleotides comprising a 5′ cap structure disclosed herein and compositions comprising the same as well as methods of making and using the same.

2.WO/2025/137542USE OF HEPARAN SULFATE (HS) OLIGOSACCHARIDES IN DISEASES
WO - 26.06.2025
Int.Class C07H 15/02
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
 Appl.No PCT/US2024/061420 Applicant THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL Inventor LIU, Jian
Disclosed are methods of treating drug-induced liver injury using synthetic heparan sulfate oligosaccharides having 12, 14, or 16 saccharide residues. For example, the drug-induced liver injury can be acetaminophen (APAP)-induced acute liver failure. Also disclosed are methods of treating sepsis using synthetic heparan sulfate oligosaccharides having 12, 14, 16, or 18 saccharide residues, as well as select 12-, 14- and 16-mer oligosaccharides and their pharmaceutical compositions.
3.20250208141FLUORESCENT PROBE FOR LABELING M1 MACROPHAGES, AND M1 MACROPHAGE MONITORING SYSTEM USING SAME
US - 26.06.2025
Int.Class G01N 33/58
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
58involving labelled substances
 Appl.No 18852010 Applicant INSTITUTE FOR BASIC SCIENCE Inventor Young-Tae CHANG

The present disclosure relates to: a novel compound comprising carbohydrate derivatives and fluorophores; a fluorescent probe for labeling M1 macrophages comprising same; and a visualization composition and kit comprising the fluorescent probe. A fluorescent probe for labeling M1 macrophages, according to one embodiment, shows excellent selectivity for M1 macrophages, and thus, the fluorescent probe can be applied to a M1 macrophage monitoring system, a method for providing information on M1 macrophages, and a method for providing information necessary for diagnosis of inflammatory diseases.

4.WO/2025/129353ERINACINE A AND ANALOGS THEREOF FOR THERAPEUTIC USE
WO - 26.06.2025
Int.Class C07C 235/40
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
CACYCLIC OR CARBOCYCLIC COMPOUNDS
235Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
40having carbon atoms of carboxamide groups bound to carbon atoms of rings other than six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
 Appl.No PCT/CA2024/051717 Applicant MCMASTER UNIVERSITY Inventor BROWN, Eric
The present application includes compounds of Formula I and II, compositions comprising these compounds and uses thereof, in particular for treatment of central nervous system (CNS) or peripheral nervous system (PNS) diseases, disorders or conditions, and for promoting or improving wound healing. (Formula I/II)
5.20250206769Synthesizing a Nucleic Acid or Nucleic Acid Analogue
US - 26.06.2025
Int.Class C07H 21/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
21Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
 Appl.No 18982920 Applicant Imec vzw Inventor Kathrin Hoelz

In a first aspect, the present disclosure relates to a method for synthesizing a nucleic acid or nucleic acid analogue, comprising: a) providing a root fragment of the nucleic acid or nucleic acid analogue, b) providing a further fragment of the nucleic acid or nucleic acid analogue, c) phosphitylating either the root fragment or the further fragment, and d) binding the further fragment to the root fragment by a phosphoramidite coupling; wherein the root fragment and the further fragment each have a length of at least 5 monomers.

6.WO/2025/130729BIOSYNTHETIC GENE CLUSTER FOR POLYENE MACROLIDE NATURAL PRODUCT MANDIMYCIN, AND NATURAL PRODUCT AND USE THEREOF
WO - 26.06.2025
Int.Class C12P 1/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
1Preparation of compounds or compositions, not provided for in groups C12P3/-C12P39/121; General processes for the preparation of compounds or compositions by using microorganisms or enzymes
06by using actinomycetales
 Appl.No PCT/CN2024/138651 Applicant CHINA PHARMACEUTICAL UNIVERSITY Inventor WANG, Zongqiang
Disclosed in the present invention are a biosynthetic gene cluster for a polyene macrolide natural product mandimycin, and a natural product and use thereof. The nucleotide sequence of the mandimycin biosynthetic gene cluster is shown in SEQ ID NO. 1, and the compound structural formulas of the natural products mandimycin and mandimycin B are shown in formula I and formula II. The natural product mandimycin of the present invention can target phospholipid molecules in fungal cell membranes, especially phosphatidylinositol, to cause efflux of important ions in fungal cells, thereby leading to the death of fungal cells. The natural products mandimycin and mandimycin B of the present invention have strong in-vivo and in-vitro antifungal activity and a broad antifungal spectrum against multiple multi-drug resistant fungal key pathogens published by WHO, comprising Candida, Aspergillus, Cryptococcus, Mucor and Fusarium.
7.WO/2025/130985COMPOUND FOR TREATING OXALIPLATIN-RESISTANT TUMORS, PREPARATION METHOD THEREFOR, COMPOSITION AND USE THEREOF
WO - 26.06.2025
Int.Class C07F 15/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
FACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
15Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
 Appl.No PCT/CN2024/140659 Applicant TIANJIN GUDUI BIO-PHARM CO., LTD. Inventor GAO, Qingzhi
A 1,1'-binaphthyl-2,2'-diamine platinum oxide for treating oxaliplatin-resistant tumors, a pharmaceutical composition thereof and the use thereof. The 1,1'-binaphthyl-2,2'-diamine platinum oxide has a structure shown as formula (I). The 1,1'-binaphthyl-2,2'-diamine platinum oxide can effectively inhibit the proliferation of oxaliplatin-resistant tumor cells and thus can be used for preparing potential drugs for treating oxaliplatin-resistant tumors.
8.WO/2025/132845GALNAC PHOSPHORAMIDITES AND THEIR USES
WO - 26.06.2025
Int.Class C07H 15/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
15Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
02Acyclic radicals, not substituted by cyclic structures
04attached to an oxygen atom of a saccharide radical
 Appl.No PCT/EP2024/087484 Applicant SILENCE THERAPEUTICS GMBH Inventor BETHGE, Lucas
The invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine phosphoramidite containing molecules, and more specifically, to variants of N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with said variants of N-Acetylgalactosamine phosphoramidite containing molecules. Further, the invention provides associated methods of producing and using these molecules, in particular, in the field of medicine. More precisely, the N-Acetylgalactosamine derivatives of the present invention bear in the position 6' a protecting group selected from TMTr, DMTr, MMTr, Fmoc, Px, DMPx.
9.WO/2025/135111NOVEL SULFONAMIDE DERIVATIVE
WO - 26.06.2025
Int.Class C07D 311/14
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
311Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
02ortho- or peri-condensed with carbocyclic rings or ring systems
04Benzo pyrans, not hydrogenated in the carbocyclic ring
06with oxygen or sulfur atoms directly attached in position 2
08not hydrogenated in the hetero ring
14substituted in position 6 and unsubstituted in position 7
 Appl.No PCT/JP2024/044954 Applicant WAKUNAGA PHARMACEUTICAL CO., LTD. Inventor SAKATA, Kotaro
The purpose of the present invention is to provide a novel compound which is useful for the suppression of TGF-β signaling, the treatment or prevention of fibrosis, obesity and diabetes, the suppression of cancer metastasis, and the enhancement of antitumor immunity.　Provided is a compound represented by formula (1) [wherein X represents an oxygen atom, a sulfur atom, or the like; Y represents a carbonyl group, a thiocarbonyl group, a sulfoxide group, or a sulfonyl group; R1 represents a lower alkyl group which may have a substituent, or the like; R2 represents a hydrogen atom, or the like; R3 represents a hydrogen atom, or the like; R4 represents a hydrogen atom, or the like; and R5 represents a hydrogen atom, or the like] or a salt thereof.
10.WO/2025/129984SYNTHESIS METHOD FOR PYRIMIDINE LOCKED NUCLEIC ACID
WO - 26.06.2025
Int.Class C07H 19/06
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
19Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro derivatives thereof
02sharing nitrogen
04Heterocyclic radicals containing only nitrogen as ring hetero atom
06Pyrimidine radicals
 Appl.No PCT/CN2024/103374 Applicant SICAGENE BIOSCIENCE CO., LTD. Inventor WANG, Haisheng
The present invention relates to a synthesis method for a pyrimidine locked nucleic acid. In the present invention, when starting from readily available commercial raw materials, a pyrimidine locked nucleic acid can be obtained only by means of three reaction steps: oxidation, aldol condensation-reduction and cyclization. The method of the present invention does not comprise any protection/deprotection operation, which remarkably shortens the synthetic route. Moreover, conventional reagents are used in the process of each reaction step, and the reaction conditions are relatively mild. The method is good in applicability and beneficial to industrial production.
# -